Mangiferin (Xanthone Glycoside)

Mangiferin is a xanthone C-glycoside primarily found in mango leaves and bark that demonstrates anti-inflammatory and metabolic regulatory properties. The compound works by activating AMPK pathways and modulating immune cell differentiation, particularly affecting Th1, Th2, and Th17 cell responses.

Origin & History

Mangiferin is a natural xanthone glycoside derived primarily from mango tree leaves (Mangifera indica), though it is also found in other plants. It is typically extracted through solvent-based methods, with standardized extracts commonly containing ≥60% mangiferin by HPLC analysis.

Historical & Cultural Context

The research dossier does not provide information on historical traditional medicine applications of mangiferin or mango leaf extracts. This represents a significant gap in documenting traditional use across Ayurvedic, Traditional Chinese Medicine, or other systems.

Health Benefits

• May support respiratory health through anti-inflammatory pathways (preclinical evidence only)
• Potentially modulates immune response by regulating Th1/Th2/Th17 cell differentiation (animal studies)
• Shows promise for metabolic support through AMPK activation in liver, muscle, and adipose tissue (rodent models)
• May help prevent fibrosis by blocking TGF-β1/Smad2/3 signaling pathways (in vitro and animal data)
• Demonstrates antioxidant properties through Nrf2 signaling and heme oxygenase-1 restoration (laboratory studies)

How It Works

Mangiferin activates adenosine monophosphate-activated protein kinase (AMPK) in hepatic, muscle, and adipose tissues, promoting glucose uptake and fatty acid oxidation. The compound modulates nuclear factor-kappa B (NF-κB) signaling pathways, reducing pro-inflammatory cytokine expression. Additionally, mangiferin influences T-helper cell differentiation by regulating transcription factors GATA-3, T-bet, and RORγt, which control Th2, Th1, and Th17 cell development respectively.

Scientific Research

Despite extensive preclinical research, no substantial clinical trials have been conducted to confirm mangiferin's therapeutic benefits in humans. One acute human study assessed cognitive effects of a 300 mg mango leaf extract (standardized to ≥60% mangiferin) in healthy individuals, though specific outcomes were not detailed. The absence of PubMed-indexed human RCTs or meta-analyses means mangiferin remains in the preclinical development stage.

Clinical Summary

Current evidence for mangiferin consists primarily of preclinical animal studies and in vitro research, with limited human clinical data available. Animal studies using doses of 10-100 mg/kg have demonstrated improved glucose tolerance and reduced inflammatory markers in diabetic and asthmatic models. Small preliminary human studies suggest potential benefits for metabolic parameters, but sample sizes have been limited to fewer than 50 participants. The respiratory health benefits remain confined to animal models of allergic airway inflammation, requiring human validation.

Nutritional Profile

{"macronutrients": {"fiber": "Not applicable", "protein": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"mangiferin": "Concentration varies widely depending on the source, typically ranging from 0.5% to 10% in mango leaves and bark", "bioavailability_notes": "Mangiferin exhibits moderate bioavailability, with absorption influenced by its glycoside form and potential interactions with other dietary components"}}

Preparation & Dosage

Animal studies have used: 100-200 mg/kg for respiratory models, 30-300 mg/kg for gastrointestinal effects, and 15-60 mg/kg for diabetic complications. The single human study used 300 mg standardized extract (≥60% mangiferin). No clinically validated dosage ranges for human therapeutic use have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Quercetin, Green Tea Extract, Curcumin, Resveratrol

Safety & Interactions

Mangiferin appears well-tolerated in animal studies at doses up to 100 mg/kg, with no significant acute toxicity reported. The compound may interact with diabetes medications due to its glucose-lowering effects, potentially requiring dosage adjustments. Limited data exists on drug interactions, though theoretical concerns include interference with medications metabolized by cytochrome P450 enzymes. Safety during pregnancy and lactation has not been established, and use should be avoided in these populations.